The tyrosine kinase Abl is required for Src-transforming activity in mouse fibroblasts and human breast cancer cells

Oncogene

Volumn 26, Issue 52, 2007, Pages 7313-7323

  Sirvent, A ^a   Boureux, A ^a,b   Simon, V ^a   Leroy, C ^a   Roche, S ^a  

^a Centre National de la Recherche Scientifique   (France)

^b INSTITUTE OF HUMAN GENETICS   (France)

Author keywords

Abl; Breast cancer; Cell transformation; ERK5; Rac; Src

Indexed keywords

ABELSON KINASE; MITOGEN ACTIVATED PROTEIN KINASE 7; PROTEIN TYROSINE KINASE; RAC PROTEIN; TYROSINE;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CARCINOGENICITY; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; FIBROBLAST; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BALB 3T3 CELLS; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; ENZYME ACTIVATION; FIBROBLASTS; HUMANS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 7; NIH 3T3 CELLS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS PP60(C-SRC); SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TYROSINE;

EID: 36148956209     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210543     Document Type: Article

References (44)

1. Barros JC, Marshall CJ. (2005). Activation of either ERK1/2 or ERK5 MAP kinase pathways can lead to disruption of the actin cytoskeleton. J Cell Sci 118: 1663-1671.
2. Boureux A, Furstoss O, Simon V, Roche S. (2005). c-Abl tyrosine kinase regulates a Rac/JNK and a Rac/Nox pathway for DNA synthesis and c-myc expression induced by growth factors. J Cell Sci 118: 3717-3726.
3. Bromann PA, Korkaya H, Courtneidge SA. (2004). The interplay between Src family kinases and receptor tyrosine kinases. Oncogene 23: 7957-7968.
4. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell Jr JE. (1998). Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 18: 2553-2558.
5. Buschbeck M, Hofbauer S, Di Croce L, Keri G, Ullrich A. (2005). Abl-kinase-sensitive levels of ERK5 and its intrinsic basal activity contribute to leukaemia cell survival. EMBO Rep 6: 63-69.
6. Chan AY, Coniglio SJ, Chuang YY, Michaelson D, Knaus UG, Philips MR et al. (2005). Roles of the Rac1 and Rac3 GTPases in human tumor cell invasion. Oncogene 24: 7821-7829.
7. Chen T, George JA, Taylor CC. (2006). Src tyrosine kinase as a chemotherapeutic target: is there a clinical case? Anticancer Drugs 17: 123-131.
8. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH et al. (2004). Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 114: 1308-1316.
9. Deroanne C, Vouret-Craviari V, Wang B, Pouyssegur J. (2003). EphrinA1 inactivates integrin-mediated vascular smooth muscle cell spreading via the Rac/PAK pathway. J Cell Sci 116: 1367-1376.
10. Dilworth SM. (2002). Polyoma virus middle T antigen and its role in identifying cancer-related molecules. Nat Rev Cancer 2: 951-956.
11. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N et al. (2007). Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/'triple- negative' breast cancer cell lines growing in vitro. Breast Cancer Res Treat: (in press) Doi 10.1007/s 10549-006-5463-x.
12. Frame MC. (2004). Newest findings on the oldest oncogene; how activated src does it. J Cell Sci 117: 989-998.
13. Franco M, Furstoss O, Simon V, Benistant C, Hong WJ, Roche S. (2006). The adaptor protein Tom1L1 is a negative regulator of Src mitogenic signaling induced by growth factors. Mol Biol Cell 26: 1932-1947.
14. Furstoss O, Dorey K, Simon V, Barilla D, Superti-Furga G, Roche S. (2002). c-Abl is an effector of Src for growth factor-induced c-myc expression and DNA synthesis. EMBO J 27: 514-524.
15. Garaude J, Cherni S, Kaminski S, Delepine E, Chable-Bessia C, Benkirane M et al. (2006). ERK5 activates NF-kappaB in leukemic T cells and is essential for their growth in vivo. J Immunol 177: 7607-7617.
16. Hantschel O, Superti-Furga G. (2004). Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol 5: 33-44.
17. Ishizawar R, Parsons SJ. (2004). c-Src and cooperating partners in human cancer. Cancer Cell 6: 209-214.
18. Kato Y, Kravchenko VV, Tapping RI, Han J, Ulevitch RJ, Lee JD. (1997). BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J 16: 7054-7066.
19. Kayahara M, Wang X, Tournier C. (2005). Selective regulation of c-jun gene expression by mitogen-activated protein kinases via the 12-O-tetradecanoylphorbol-13-acetate- responsive element and myocyte enhancer factor 2 binding sites. Mol Cell Biol 25: 3784-3792.
20. Kovalenko M, Ronnstrand L, Heldin CH, Loubtchenkov M, Gazit A, Levitzki A et al. (1997). Phosphorylation site-specific inhibition of platelet-derived growth factor beta-receptor autophosphorylation by the receptor blocking tyrphostin AG1296. Biochemistry 36: 6260-6269.
21. Krause DS, Van Etten RA. (2005). Tyrosine kinases as targets for cancer therapy. N Engl J Med 353: 172-187.
22. Lewis JM, Baskaran R, Taagepera S, Schwartz MA, Wang JY. (1996). Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. Proc Natl Acad Sci USA 93: 15174-15179.
23. Martin GS. (2001). The hunting of the Src. Nat Rev Mol Cell Biol 2: 467-475.
24. Minden A, Lin A, Claret FX, Abo A, Karin M. (1995). Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 81: 1147-1157.
25. Mulloy R, Salinas S, Philips A, Hipskind RA. (2003). Activation of cyclin D1 expression by the ERK5 cascade. Oncogene 22: 5387-5398.
26. Nicholson PR, Empereur S, Glover HR, Dilworth SM. (2001). ShcA tyrosine phosphorylation sites can replace ShcA binding in signalling by middle T-antigen. EMBO J 20: 6337-6346.
27. Pendergast AM. (2002). The Abl family kinases: mechanisms of regulation and signaling. Adv Cancer Res 85: 51-100.
28. Plattner R, Irvin BJ, Guo S, Blackburn K, Kazlauskas A, Abraham RT et al. (2003). A new link between the c-Abl tyrosine kinase and phosphoinositide signalling through PLC-gamma1. Nat Cell Biol 5: 309-319.
29. Plattner R, Kadlec L, DeMali KA, Kazlauskas A, Pendergast AM. (1999). c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev 13: 2400-2411.
30. Roussidis AE, Mitropoulou TN, Theocharis AD, Kiamouris C, Papadopoulos S, Kletsas D et al. (2004). STI571 as a potent inhibitor of growth and invasiveness of human epithelial breast cancer cells. Anticancer Res 24: 1445-1447.
31. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM et al. (2007). Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445: 437-441.
32. Servitja JM, Marinissen MJ, Sodhi A, Bustelo XR, Gutkind JS. (2003). Rac1 function is required for Src-induced transformation. Evidence of a role for Tiam1 and Vav2 in Rac activation by Src. J Biol Chem 278: 34339-34346.
33. Sini P, Cannas A, Koleske AJ, Di Fiore PP, Scita G. (2004). Abl-dependent tyrosine phosphorylation of Sos-1 mediates growth-factor-induced Rac activation. Nat Cell Biol 6: 268-274.
34. Srinivasan D, Plattner R. (2006). Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells. Cancer Res 66: 5648-5655.
35. Suzuki J, Sukezane T, Akagi T, Georgescu MM, Ohtani M, Inoue H et al. (2004). Loss of c-abl facilitates anchorage-independent growth of p53- and RB-deficient primary mouse embryonic fibroblasts. Oncogene 23: 8527-8534.
36. Tanis KQ, Veach D, Duewel HS, Bornmann WG, Koleske AJ. (2003). Two distinct phosphorylation pathways have additive effects on Abl family kinase activation. Mol Cell Biol 23: 3884-3896.
37. Turkson J, Bowman T, Adnane J, Zhang Y, Djeu JY, Sekharam M et al. (1999). Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Mol Cell Biol 19: 7519-7528.
38. Urich M, Senften M, Shaw PE, Ballmer-Hofer K. (1997). A role for the small GTPase Rac in polyomavirus middle-T antigen-mediated activation of the serum response element and in cell transformation. Oncogene 14: 1235-1241.
39. Ushio-Fukai M, Zuo L, Ikeda S, Tojo T, Patrushev NA, Alexander RW. (2005). cAbl tyrosine kinase mediates reactive oxygen species- and caveolin-dependent AT1 receptor signaling in vascular smooth muscle: role in vascular hypertrophy. Circ Res 97: 829-836.
40. Veracini L, Franco M, Boureux A, Simon V, Roche S, Benistant C. (2006). Two distinct pools of Src family tyrosine kinases regulate PDGF-induced DNA synthesis and actin dorsal ruffles. J Cell Sci 20: 2921-2934.
41. Yang L, Lin C, Liu ZR. (2006). P68 RNA helicase mediates PDGF-induced epithelial mesenchymal transition by displacing Axin from beta-catenin. Cell 127: 139-155.
42. Yeatman TJ. (2004). A renaissance for SRC. Nat Rev Cancer 4: 470-480.
43. Zipfel PA, Zhang W, Quiroz M, Pendergast AM. (2004). Requirement for Abl kinases in T-cell receptor signaling. Curr Biol 14: 1222-1231.
44. Zou X, Calame K. (1999). Signaling pathways activated by oncogenic forms of Abl tyrosine kinase. J Biol Chem 274: 18141-18144.